Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Pretax loss widens to £249,000 in the six months to December 31 compared with £235,000 a year prior as revenue dips 12% to £329,000 from £374,000. Highlights strong pipeline with four contracts won in the first half of the financial year. Based on these signed contracts, the company expects total income for the current financial year will be in line with market expectations, with additional contracted revenue projected into next year - year to June 2026. The company is ‘actively progressing’ a number of late-stage opportunities, however, there is no guarantee that these contracts will be signed within the current financial year.
Current stock price: 0.43 pence, down 7.8% in London on Wednesday
12-month change: down 69%
Copyright 2025 Alliance News Ltd. All Rights Reserved.